← Back to headlines
Immunic Appoints Erik Lundgren as CEO to Advance Phase 3 MS Trials
Immunic has announced the appointment of Erik Lundgren, a former Genentech executive, as its new Chief Executive Officer, tasked with advancing the company's Phase 3 MS trials.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
SM Entertainment and Tencent Music Form Joint Venture for New Chinese Idol Group
24m ago
Apple Stock Hits Record as Leadership Changes and iPhone 18 Debuts
28m ago
Bank of Korea Raises Interest Rates to 3 Percent for Second Consecutive Session
35m ago
Canada Launches Retaliatory Tariffs Against Trump in Escalating Trade War
43m ago